Ligand Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
(technical difficulty) from Barclays and for the next session of the day, we have John Higgins, CEO from Ligand Pharmaceuticals. John, over to you.
Thank you, [Balaji]. I appreciate the introduction, and it's a pleasure to be here. Bear with my -- I have a slight winter cold. Soon to be springtime though, so bring on the sun. It's nice to be here in Miami. We arrived last evening. We were in New York City yesterday. We had our Analyst Day. Once a year, we host Analyst Day and these slides you'll see today are representing a lot of new content from that program in New York. It was a well-attended event. We're happy to be here.
Ligand, I recognize a few faces, faces we've known from the past, a few new faces, perhaps. I'm going to be talking about the business, giving forward-looking statements, describing our outlook on the business, risks the company face are represented in our SEC filed documents. We encourage you to review those documents for a full
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |